Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Topics Lawsuit

April 02, 2026

From SkyMedia, LLC

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

2 Cash-Heavy Stocks Worth Your Attention and 1 We Find Risky

April 02, 2026

Via StockStory

Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026

April 01, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026

Topics Lawsuit

April 01, 2026

NEW YORK, NY - April 1, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Topics Lawsuit

March 31, 2026

From Kahn Swick & Foti, LLC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

March 31, 2026

From Pomerantz LLP

Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines

March 31, 2026

From Bragar Eagel & Squire

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

Via MarketMinute

Topics ETFs Intellectual Property Stocks

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

March 30, 2026

From Schall Law

Shareholders of Corcept would probably like to forget the past six months even happened. The stock dropped 56.3% and now trades at $36.31. This was partly dr...

3 Reasons to Avoid CORT and 1 Stock to Buy Instead

March 30, 2026

Via StockStory

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

March 28, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox

March 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox

Topics Lawsuit

March 28, 2026

NEW YORK, NY - March 28, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

It was a historic stretch of time for the biotech.

Topics Lawsuit

Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week ↗

March 27, 2026

Via The Motley Fool

CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox

March 27, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox

Topics Fraud Lawsuit

March 27, 2026

NEW YORK, NY - March 27, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT

Topics Fraud Lawsuit

March 26, 2026

From The Rosen Law Firm PA

Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026

March 26, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026

Topics Lawsuit

March 26, 2026

NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

Topics Lawsuit

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...

Via Finterra

Topics Economy Intellectual Property

March 25, 2026

From SkyMedia, LLC

A top regulator approved one of its drugs that afternoon.

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗

March 25, 2026

Via The Motley Fool

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

March 25, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

What's Behind The Jump In Corcept Therapeutics Stock? ↗

March 25, 2026

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary...

Via Benzinga

Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026

March 25, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026

Topics Lawsuit

March 25, 2026

NEW YORK, NY - March 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...